While immune checkpoint inhibitors provide significant anti-tumor efficacy, they may also trigger immune-related adverse events requiring multidisciplinary collaborative management. 免疫检查点抑制剂在带来显著抗肿瘤疗效的同时,也可能引发免疫相关不良事件,需要多学科协作管理。